| 0.6932 -0.114 (-14.17%) | 12-15 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.96 |
1-year : | 1.13 |
| Resists | First : | 0.82 |
Second : | 0.97 |
| Pivot price | 0.73 |
|||
| Supports | First : | 0.58 |
Second : | 0.48 |
| MAs | MA(5) : | 0.8 |
MA(20) : | 0.74 |
| MA(100) : | 1.21 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 67.2 |
D(3) : | 78.4 |
| RSI | RSI(14): 43.8 |
|||
| 52-week | High : | 2.78 | Low : | 0.32 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IOBT ] has closed above bottom band by 33.6%. Bollinger Bands are 68.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 28 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.8 - 0.81 | 0.81 - 0.81 |
| Low: | 0.67 - 0.68 | 0.68 - 0.68 |
| Close: | 0.69 - 0.69 | 0.69 - 0.7 |
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Mon, 15 Dec 2025
IO Biotech Publishes Five-Year Results from MM1636 Trial Showing Potential of IO102-IO103 in Metastatic Melanoma Treatment - Quiver Quantitative
Mon, 15 Dec 2025
IO Biotech (NASDAQ: IOBT) 5-year data show 60-month OS, >53-month responses - Stock Titan
Sun, 14 Dec 2025
IO Biotech, Inc. (NASDAQ:IOBT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Sat, 13 Dec 2025
IO Biotech (NASDAQ:IOBT) Stock Rating Lowered by Wall Street Zen - MarketBeat
Wed, 26 Nov 2025
IO Biotech (Nasdaq: IOBT) to Join Evercore, Piper Sandler December Investor Events - Stock Titan
Wed, 19 Nov 2025
IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's Why - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 72 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 5.1 (%) |
| Held by Institutions | 48.1 (%) |
| Shares Short | 2,850 (K) |
| Shares Short P.Month | 2,760 (K) |
| EPS | -1.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -88.6 % |
| Return on Equity (ttm) | -240.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.28 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -81 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -0.52 |
| PEG Ratio | 0 |
| Price to Book value | 69.31 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|